Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
Introduction Gene transfer vectors require the efficient transduction of target cells, stable association with the host genome, and adequate transgene expression in the appropriate target cell, without associated toxic or immunological side effects. Currently available viral vector systems, including recombinant retroviruses, adenoviruses and adeno-associated viruses(AAV), are not suitable for efficient gene transfer into many cell types. Retroviral vectors require cell division for stable integration. Recombinant adenoviruses are not able to infect many cell types important for gene therapy, including hematopoeitic stem cells, monocytes, T- and B-lymphocytes. Moreover, recombinant adeno-associated vectors integrate with low frequency. Therefore, there is a present need for an improved vectors which can be targeted efficiently to a variety of cell types and tissues and remain stably integrated in the host genome with minimal antigenicity to the host. Technology description The present invention discloses novel chimeric adenoviral (Ad) Ad-AAV vectors, which express a modified fiber protein on their capsid, for specifically targeting the vector. Methods of making, uses and advantages of these vectors are provided. In addition, the inventors provide a novel approach to retarget any adenovirus serotype for cell specific infection. Business Opportunity There are more than 6,000 known single-gene disorders, which occur in about 1 out of every 200 births. Some examples are cystic fibrosis, sickle cell anemia, Marfan syndrome, Huntington’s disease, and hereditary hemochromatosis. One of the limitations of gene therapy lies in the stability of vectors used for gene transfer. This new adenoviral vector allows high titer transgene delivery, cell specific infection, the ability to stably integrate into the host genome and represents promising avenues for future gene therapy strategies. Intellectual Property Position Issued US Patent 7,094,398: Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration. For more information on this technology contact:
Angela Loihl, Ph.D. Licensing Officer, Invention Licensing UW TechTransfer [email protected] 206-897-1982
Type of Offer: Licensing
« More Medical Patents